The impact of short-course hypofractionated radiotherapy on multimodality treatment utilisation, compliance, and outcome in glioblastoma patients: a Danish patterns of care study

References

• Berger TR, Wen PY, Lang-Orsini M, et al. World health organization 2021 classification of Central nervous system tumors and implications for therapy for adult-type gliomas: a review. JAMA Oncol. 2022;8(10):1493–1501. doi: 10.1001/jamaoncol.2022.2844.
   PubMed Web of Science ®Google Scholar
• Michael W, Martin van den B, Matthias P. et al. EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood. Nat Rev Clin Oncol. 2021;18:170–186.
   PubMed Web of Science ®Google Scholar
• Gzell C, Back M, Wheeler H, et al. Radiotherapy in glioblastoma: the past, the present and the future. Clin Oncol (R Coll Radiol). 2017;29(1):15–25. doi: 10.1016/j.clon.2016.09.015.
   PubMed Web of Science ®Google Scholar
• Niyazi M, Andratschke N, Bendszus M, et al. ESTRO-EANO guideline on target delineation and radiotherapy details for glioblastoma. Radiother Oncol. 2023;184:109663.
   PubMed Web of Science ®Google Scholar
• Stupp R, Mason WP, Van Den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987–996. doi: 10.1056/NEJMoa043330.
   PubMed Web of Science ®Google Scholar
• Stupp R, Taillibert S, Kanner AA, et al. Maintenance therapy with tumor-treating fields plus temozolomide vs temozolomide alone for glioblastoma a randomized clinical trial. JAMA 2015;314(23):2535–2543. doi: 10.1001/jama.2015.16669.
   PubMed Web of Science ®Google Scholar
• Gorlia T, van den Bent MJ, Hegi ME, et al. Nomograms for predicting survival of patients with newly diagnosed glioblastoma: prognostic factor analysis of EORTC and NCIC trial 26981-22981/CE.3. Lancet Oncol. 2008;9(1):29–38. doi: 10.1016/S1470-2045(07)70384-4.
   PubMed Web of Science ®Google Scholar
• Malmström A, Grønberg BH, Marosi C, et al. Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial. Lancet Oncol. 2012;13(9):916–926. doi: 10.1016/S1470-2045(12)70265-6.
   PubMed Web of Science ®Google Scholar
• Hulshof MCCM, Schimmel EC, Andries Bosch D, et al. Hypofractionation in glioblastoma multiforme. Radiother Oncol. 2000;54(2):143–148.
   PubMed Web of Science ®Google Scholar
• Brodbelt A, Greenberg D, Winters T, et al. Glioblastoma in England: 2007-2011. Eur J Cancer. 2015;51(4):533–542.
   PubMed Web of Science ®Google Scholar
• Brown NF, Ottaviani D, Tazare J, et al. Survival outcomes and prognostic factors in glioblastoma. Cancers (Basel). 2022;:14(13):3161.
   Google Scholar
• Roa W, Brasher PMA, Bauman G, et al. Abbreviated course of radiation therapy in older patients with glioblastoma multiforme: a prospective randomized clinical trial. J Clin Oncol. 2004;22(9):1583–1588. doi: 10.1200/JCO.2004.06.082.
   PubMed Web of Science ®Google Scholar
• Perry JR, Laperriere N, O’Callaghan CJ, et al. Short-course radiation plus temozolomide in elderly patients with glioblastoma. N Engl J Med. 2017;376(11):1027–1037. doi: 10.1056/NEJMoa1611977.
   PubMed Web of Science ®Google Scholar
• Weller M, van den Bent M, Tonn JC, et al. European Association for Neuro-Oncology (EANO) guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas. Lancet Oncol. 2017;18(6):e315–e329. doi: 10.1016/S1470-2045(17)30194-8.
   PubMed Web of Science ®Google Scholar
• Weller M, van den Bent M, Hopkins K, et al. EANO guideline for the diagnosis and treatment of anaplastic gliomas and glioblastoma. Lancet Oncol. 2014;15(9):e395–e403.
   PubMed Web of Science ®Google Scholar
• Morgan ER, Norman A, Laing K, et al. Treatment and outcomes for glioblastoma in elderly compared with non-elderly patients: a population-based study. Curr Oncol. 2017;24(2):e92–e98. doi: 10.3747/co.24.3424.
   PubMed Web of Science ®Google Scholar
• Nead KT, Swisher-McClure S. Utilization of hypofractionated radiation therapy in older glioblastoma patients. J Geriatr Oncol. 2019;10(1):155–158. doi: 10.1016/j.jgo.2018.06.006.
   PubMed Web of Science ®Google Scholar
• Haque W, Verma V, Butler EB, et al. Patterns of care and outcomes of hypofractionated chemoradiation Versus conventionally fractionated chemoradiation for glioblastoma in the elderly population. Am J Clin Oncol. 2018;41(2):167–172. doi: 10.1097/COC.0000000000000417.
   PubMed Web of Science ®Google Scholar
• Hansen S. The Danish neuro-oncology registry. Clin Epidemiol. 2016;8:629–632. doi: 10.2147/CLEP.S99459.
   PubMed Web of Science ®Google Scholar
• Karschnia P, Vogelbaum MA, van den Bent M, et al. Evidence-based recommendations on categories for extent of resection in diffuse glioma. Eur J Cancer. 2021;149:23–33. doi: 10.1016/j.ejca.2021.03.002.
   PubMed Web of Science ®Google Scholar
• Roa W, Kepka L, Kumar N, et al. International Atomic Energy Agency randomized phase III study of radiation therapy in elderly and/or frail patients with newly diagnosed glioblastoma multiforme. J Clin Oncol. 2015;33(35):4145–4150. doi: 10.1200/JCO.2015.62.6606.
   PubMed Web of Science ®Google Scholar
• Gulati S, Jakola AS, Johannesen TB, et al. Survival and treatment patterns of glioblastoma in the elderly: a population-based study. World Neurosurg. 2012;78(5):518–526. doi: 10.1016/j.wneu.2011.12.008.
   PubMed Web of Science ®Google Scholar
• Graus F, Bruna J, Pardo J, et al. Patterns of care and outcome for patients with glioblastoma diagnosed during 2008-2010 in Spain. Neuro Oncol. 2013;15(6):797–805. doi: 10.1093/neuonc/not013.
   PubMed Web of Science ®Google Scholar
• Fabbro-Peray P, Zouaoui S, Darlix A, et al. Association of patterns of care, prognostic factors, and use of radiotherapy-temozolomide therapy with survival in patients with newly diagnosed glioblastoma: a French national population-based study. J Neurooncol. 2019;;142(1):91–101. doi: 10.1007/s11060-018-03065-z.
   PubMed Web of Science ®Google Scholar
• Brandes AA, Franceschi E, Ermani M, et al. Pattern of care and effectiveness of treatment for glioblastoma patients in the real world: results from a prospective population-based registry. Could survival differ in a high-volume center? Neurooncol Pract. 2014;;1(4):166–171. doi: 10.1093/nop/npu021.
   PubMedGoogle Scholar
• Woo PYM, Yau S, Lam T-C, et al. Patterns of care and survival of Chinese glioblastoma patients in the temozolomide era: a Hong Kong population-level analysis over a 14-year period. Neurooncol Pract. 2023;10(1):50–61. doi: 10.1093/nop/npac069.
   PubMed Web of Science ®Google Scholar
• Efremov L, Abera SF, Bedir A, et al. Patterns of glioblastoma treatment and survival over a 16-years period: pooled data from the German Cancer Registries. J Cancer Res Clin Oncol. 2021;147(11):3381–3390. doi: 10.1007/s00432-021-03596-5.
   PubMed Web of Science ®Google Scholar
• Haque W, Verma V, Butler EB, et al. Addition of chemotherapy to hypofractionated radiotherapy for glioblastoma: practice patterns, outcomes, and predictors of survival. J Neurooncol. 2018;136(2):307–315. doi: 10.1007/s11060-017-2654-y.
   PubMed Web of Science ®Google Scholar
• Biau J, Chautard E, De Schlichting E, et al. Radiotherapy plus temozolomide in elderly patients with glioblastoma: a “real-life” report. Radiat Oncol. 2017;12(1):197. doi: 10.1186/s13014-017-0929-2.
   PubMedGoogle Scholar
• Amsbaugh MJ, Yusuf MB, Gaskins J, et al. Patterns of care and predictors of adjuvant therapies in elderly patients with glioblastoma: an analysis of the National Cancer Data Base. Cancer 2017;123(17):3277–3284. doi: 10.1002/cncr.30730.
   PubMed Web of Science ®Google Scholar